A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score

• Published in: BMC cancer 2024-01, Vol.24 (1), p.73-73, Article 73
• Main Authors: Zhao, Zixuan, Gu, Shuyan, Yang, Yi, Wu, Weijia, Du, Lingbin, Wang, Gaoling, Dong, Hengjin
• Format: Article
• Language: English
• Subjects: Age; Aged; Analysis; Cancer screening; Care and treatment; Cohort analysis; Computed tomography; Cost analysis; Cost benefit analysis; Cost-effectiveness; Cost-Effectiveness Analysis; CT imaging; Diagnosis; Drug dosages; Early Detection of Cancer - methods; Genetic Risk Score; Health aspects; Humans; LDCT screening; Lung cancer; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - genetics; Markov modelling; Mass Screening; Medical prognosis; Medical screening; Methods; Middle Aged; Polygenic Risk Score; Quality-Adjusted Life Years; Sensitivity analysis; Smokers; Tomography; Tomography, X-Ray Computed - methods
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11800-7

Several studies have proved that Polygenic Risk Score (PRS) is a potential candidate for realizing precision screening. The effectiveness of low-dose computed tomography (LDCT) screening for lung cancer has been proved to reduce lung cancer specific and overall mortality, but the cost-effectiveness of diverse screening strategies remained unclear. The comparative cost-effectiveness analysis used a Markov state-transition model to assess the potential effect and costs of the screening strategies incorporating PRS or not. A hypothetical cohort of 300,000 heavy smokers entered the study at age 50-74 years and were followed up until death or age 79 years. The model was run with a cycle length of 1 year. All the transition probabilities were validated and the performance value of PRS was extracted from published literature. A societal perspective was adopted and cost parameters were derived from databases of local medical insurance bureau. Sensitivity analyses and scenario analyses were conducted. The strategy incorporating PRS was estimated to obtain an ICER of CNY 156,691.93 to CNY 221,741.84 per QALY gained compared with non-screening with the initial start age range across 50-74 years. The strategy that screened using LDCT alone from 70-74 years annually could obtain an ICER of CNY 80,880.85 per QALY gained, which was the most cost-effective strategy. The introduction of PRS as an extra eligible criteria was associated with making strategies cost-saving but also lose the capability of gaining more LYs compared with LDCT screening alone. The PRS-based conjunctive screening strategy for lung cancer screening in China was not cost-effective using the willingness-to-pay threshold of 1 time Gross Domestic Product (GDP) per capita, and the optimal screening strategy for lung cancer still remains to be LDCT screening for now. Further optimization of the screening modality can be useful to consider adoption of PRS and prospective evaluation remains a research priority.